

Spinal Muscular Atrophy (SMA)

A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)

Trial Status
Completed

Trial Runs In
7 Countries

Trial Identifier
NCT02628743 2015-001589-25
BN29854

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this open-label, single arm study is to further evaluate long-term tolerability, safety and efficacy outcomes of olesoxime in participants with Spinal Muscular Atrophy (SMA) who previously participated in one of the following two clinical studies: TRO19622 CL E Q 1115-1 (open-label Phase Ib, multicenter, single- and multiple- dose study) or TRO19622 CL E Q 1275-1 (NCT01302600, Phase II/III, adaptive, parallel-group, double blind, randomized, placebo-controlled, multicenter, multinational study).

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT02628743 2015-001589-25 BN29854
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
All

Healthy Volunteers
No